Sign in

Alyssa Waxenberg

About Alyssa Waxenberg

Alyssa Waxenberg (age 54) has served as an independent director of KinderCare Learning Companies, Inc. since 2021; her current Class III term runs through the 2027 annual meeting. She is Senior Director of Patient Digital Products & Experience at Quest Diagnostics (since 2021) and holds a B.B.A. from the University of Massachusetts and an M.B.A. from the University of Michigan. Her core credentials span digital commerce/product, consumer experience, and strategic growth across healthcare, tech, and hospitality sectors .

Past Roles

OrganizationRoleTenureCommittees/Impact
Independent Pet PartnersChief Digital Officer2018–2020Led digital, retail, education, and services in pet wellness
IBM (Watson Marketing)Director2017–2018Product/marketing leadership within AI-enabled marketing suite
Starwood Hotels & ResortsVP, Mobile & Consumer Experience; senior digital roles2004–2016Scaled consumer/mobile experience in global hospitality

External Roles

OrganizationRoleTenureNotes
Quest DiagnosticsSenior Director, Patient Digital Products & Experience2021–presentLeads consumer-facing digital products

Board Governance

  • Board classification and tenure: Class III director, term expiring at the 2027 annual meeting .
  • Independence: The Board determined Ms. Waxenberg is independent under NYSE rules .
  • Committee assignments: Audit Committee member; Audit Chair is Michael Nuzzo. Audit Committee met two times in FY2024 subsequent to IPO. The Board designated her “financially literate” under SEC/NYSE standards .
  • Attendance and engagement: After the IPO, the Board met four times in FY2024; all directors attended at least 75% of board and applicable committee meetings. Directors are expected to attend annual meetings .
  • Board leadership: Chair of the Board is John T. (“Tom”) Wyatt; Lead Independent Director is Jean Desravines, who presides over executive sessions of independent directors .

Fixed Compensation

ComponentAmountPeriod/Notes
Annual retainer (cash)$100,000Stipend per offer letter (paid quarterly)
Cash in lieu of equity (annual director grant)$110,000Paid in cash for FY2024 in lieu of equity
Committee chair fees$0No chair role; Audit Chair stipend applies to Nuzzo ($25,000)
Meeting/other fees$0 disclosedNo meeting fees disclosed
All other compensation (expense reimbursements)$1,319FY2024
Total director compensation (cash)$210,000FY2024 total fees earned

Notes:

  • Non-employee directors serving as of Dec 28, 2024 held no equity awards in the Company. KinderCare expects to adopt a non-employee director compensation program with equity grants in connection with the 2025 Annual Meeting .

Performance Compensation

Performance-based componentMetric(s)Target/StructureFY2024 Status
Director equity grantEquity retainer (RSUs/DSUs expected)To be adopted with 2025 programNot granted in FY2024; cash paid in lieu
Performance-linked director payN/AN/ANone disclosed

Other Directorships & Interlocks

CategoryDetails
Current public company boardsNone disclosed beyond KLC
Committee roles at other public companiesNone disclosed
Interlocks (comp committee or management ties)No compensation committee interlocks disclosed involving Ms. Waxenberg; comp committee comprises Deputy (Chair), Nuzzo, Schwartz, all independent

Expertise & Qualifications

  • Education: B.B.A. (University of Massachusetts); M.B.A. (University of Michigan) .
  • Technical expertise: Digital e-commerce/product leadership, consumer experience, multi-site operations; “financially literate” for Audit Committee service .
  • Industry experience: Healthcare diagnostics (Quest), technology (IBM Watson Marketing), hospitality (Starwood) .

Equity Ownership

HolderShares Beneficially Owned% of OutstandingComponents/Notes
Alyssa Waxenberg5,793<1%Includes 3,594 shares issuable within 60 days of Apr 11, 2025 upon RSU vesting

Additional ownership context:

  • As of Dec 28, 2024, non-employee directors held no equity awards; however, the April 11, 2025 beneficial ownership table includes director RSUs vesting within 60 days, including for Ms. Waxenberg, reflecting post-IPO award conversions/timing .
  • Pledging/hedging: No pledging or hedging disclosures specific to Ms. Waxenberg; Company maintains insider trading policy (see 10-K exhibits) .

Governance Assessment

  • Strengths:

    • Independent director with Audit Committee service and financial literacy, supporting oversight of financial reporting, controls, and related-party reviews .
    • Diverse digital/consumer product expertise from healthcare and hospitality sectors, additive to KinderCare’s service-centric model .
    • Attendance threshold met; board has established annual evaluations and clear leadership/independence structures (Lead Independent Director) .
  • Alignment and incentives:

    • FY2024 director pay was cash-heavy ($210,000) with $110,000 cash in lieu of equity; equity-based alignment is expected to improve with the adoption of a 2025 equity grant program for non-employee directors .
    • Personal ownership is modest (<1%); RSUs vesting in 2025 strengthen alignment but overall stake remains small versus outstanding shares .
  • Conflicts and red flags:

    • No related-party transactions disclosed involving Ms. Waxenberg; Audit Committee has explicit oversight and approval of related-person transactions .
    • Partners Group retains nomination rights and committee representation while it owns significant voting power, which can influence board composition; Ms. Waxenberg is not a PG designee and is classified independent .
    • No disclosures of low attendance, tax gross-ups, pledging, or legal proceedings relating to Ms. Waxenberg .
  • Implications for investors:

    • Audit Committee placement and independence status are positives for governance and risk oversight; forthcoming equity grants should enhance ownership alignment. Monitor the director compensation program design post-2025 Annual Meeting and any updates to director stock ownership guidelines, as the comp committee is charged with recommending such guidelines for non-employee directors .